
Get started
Sign in
Close

Research

Featured research

CDC publishes national COVID-19 analysis using Truveta Data in the MMWR

CDC publishes national COVID-19 analysis using Truveta Data

Older adults remain at highest risk for COVID-19–related hospitalization. Yet a new CDC analysis suggests that effective antiviral treatments are likely underprescribed among outpatients aged 65 or older, with prescribing patterns varying alongside disease...
Read More
Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval – Truveta research report cover image.

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...
Read More
Truveta Research graphic announcing a Contraception journal study evaluating lidocaine and opioid use during IUD insertion.

Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025

Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
Read More
Respiratory virus monitoring report, data through December 2025

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through December 2025 

Respiratory virus–associated hospitalizations increased substantially (+125.3%) in December 2025 and accounted for nearly 7% of all hospitalizations by the last week of the month. This increase was driven primarily by a rise in influenza-associated hospitalizations...
Read More
Graphic with the Truveta logo and the headline ‘Rising use of GLP-1 medications among women with PCOS,’ set on a blue background with stylized ascending bar shapes representing increasing medication use.

Rising use of GLP-1 medications among women with PCOS

Among women prescribed a semaglutide or tirzepatide medication, the percentage with a PCOS diagnosis increased from 4.6% in 2021 to 5.7% in 2025, a 23.9% relative increase. Nearly all PCOS patients prescribed semaglutide or tirzepatide also had obesity or type 2...
Read More

Featured research topics

GLP-1

Oncology

Flu/RSV

Measles

Cardiovascular